Jan 29 (Reuters) - Insulin delivery device maker Beta

Bionics said on Wednesday it raised $204 million in its initial

public offering (IPO) at a valuation of about $700 million.

The U.S.-based company said it priced its IPO at $17 per

share, the upper-end of its forecasted range of $16 to $17 per

share.

The size of the offering was raised to 12 million shares

from 10 million shares, the company said.

Beta bucks the recent trend where major IPO candidates such

as LNG exporter Venture Global ( VG ) and pork producer

Smithfield Foods ( SFD ) had to lower their valuation targets.

Beta's shares will start trading on the Nasdaq under the

symbol "BBNX" on Thursday.

BofA Securities, Piper Sandler, Leerink Partners, Stifel and

Lake Street are the underwriters for the offering.